GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

2024 ESMO Annual Meeting Insights Hub

H. Hochster

ESMO 2024 Summary: Highlights in CRC and Impacts on Practice

2024 ESMO Annual Meeting Insights Hub

R. Kim, T. Biachi

Organ Preservation in Rectal Cancer: Neoadjuvant Short-Course RT vs.…

Memorial Sloan Kettering Cancer Center

P. Romesser

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

1L Botensilimab + Balstilimab in Stage IV MSS CRC Without Liver Mets…

Nicholas DeVito

ESMO 2024 Insights: NO-CUT Trial - Total Neoadjuvant Treatment Witho…

ecancer

A. Amatu

Year in Review: Colorectal Cancer

Moffitt Cancer Center

R. Kim, T. Biachi

Anal Cancer Staging and Treatment Options

GRACE

P. Romesser

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

History of Cancer and Its Treatment: What Will It Take to Cure?

University of Colorado Cancer Center

C. Lieu

ESMO 2024 Insights: The Value of Immune Checkpoint Blockade in MSS/p…

2024 ESMO Annual Meeting Insights Hub

B. Geisler

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

ASCO® 2024 Summary: "Expert Panel Discussion on CRC Including TRANSM…

2024 ASCO® Annual Meeting Insights Hub

N. Uboha, K. Spencer, M. Cecchini

Treating KRAS-Mutated mCRC

Ibrahim Sahin

Anti-EGFR Therapy in CRC: How to Manage Toxicities

Ibrahim Sahin

Guidance on Incorporating Anti-EGFR Therapy in 1L CRC Practice

Ibrahim Sahin

2024 Updates on 1L MSI-H/dMMR mCRC and Using ctDNA MRD Testing in Ea…

Total Health

A. Grothey

ASCO® 2024 Insights: "PanaMa Trial - FU/FA Maintenance Therapy With …

2024 ASCO® Annual Meeting Insights Hub

D. Modest

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

2024 ASCO® Annual Meeting Insights Hub

C. Eng